

# Medical Policy

## Healthcare Services Department

Policy Name	Policy Number	Scope
Mirikizumab-mrkz (Omvoh®)	MP-RX-FP-125-24	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

### Service Category

- |  |   |
|--|---|
| <input type="checkbox"/> Anesthesia                          | <input type="checkbox"/> Medicine Services and Procedures   |
| <input type="checkbox"/> Surgery                             | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures                | <input type="checkbox"/> DME/Prosthetics or Supplies        |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Part B Drugs            |

### Service Description

This document addresses the use of *Mirikizumab-mrkz (Omvoh®)*, an interleukin-23 antagonist approved by the Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis in adults.

### Background Information

Mirikizumab is a monoclonal antibody that selectively bind to the specific protein p19 subunit of human IL-23 cytokine and inhibits the IL-23 pathway indicated for the treatment of moderately to severely active ulcerative colitis in adults.

#### *Ulcerative Colitis*

For those with moderately to severely active disease, the American College of Gastroenterology (ACG) guidelines strongly recommend induction of remission using oral budesonide MMX, oral systemic corticosteroids, TNFi, tofacitinib or vedolizumab (moderate to high quality evidence). The American Gastroenterological Association (AGA) guidelines define moderate to severe UC as those who are dependent on or refractory to corticosteroids, have severe endoscopic disease activity, or are at high risk of colectomy. AGA strongly recommends biologics (TNFi, vedolizumab, or ustekinumab) or tofacitinib over no treatment in induction and maintenance of remission (moderate quality of evidence). For biologic-naïve individuals, Infliximab or vedolizumab are conditionally recommended over adalimumab for induction of remission (moderate quality evidence). Guidelines precede FDA approval of mirikizumab for UC.

### Approved Indications

- A. Treatment of moderately to severely active ulcerative colitis in adults.

### Other Uses

- i. None

# Medical Policy

## Healthcare Services Department

<b>Policy Name</b> <b>Mirikizumab-mrkz (Omvo®)</b>	<b>Policy Number</b> MP-RX-FP-125-24	<b>Scope</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
---	---	--

### Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPSCS	Description
J2267	Injection, mirikizumab-mrkz, 1 mg [Omvo®]

ICD-10	Description
K51.00 – K51.919	Ulcerative colitis

Policy Name	Policy Number	Scope
Mirikizumab-mrkz (Omvoh®)	MP-RX-FP-125-24	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

### Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

### Mirikizumab-mrkz (Omvoh®)

**A. Criteria For Initial Approval** *(Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.)*

- i. Ulcerative colitis (UC) when the following criteria are met:
  - A. For individuals requesting intravenous induction doses:
    - 1. Individual is 18 years of age or older with moderate to severe UC; **AND**
    - 2. Individual has had an inadequate response to or is intolerant of conventional therapy (such as 5-Aminosalicylic acid products, systemic corticosteroids, or immunosuppressants [such as thiopurines]);
    - OR**
    - 3. Individual has a contraindication to 5-ASA products or systemic corticosteroids or thiopurines;
  - OR**
  - B. For individuals requesting subcutaneous maintenance therapy:
    - 1. Individual is 18 years of age or older with moderate to severe UC; **AND**
    - 2. Individual has completed the intravenous induction doses with Omvoh and will be using subcutaneous Omvoh for maintenance therapy.

**B. Criteria For Continuation of Therapy**

- i. MMM considers continuation of Mirikizumab-mrkz (Omvoh®) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) if the following information is provided:
  - A. Documentation that the patient has been receiving and is maintained on a stable dose of Omvoh; **AND**
  - B. There is clinically significant improvement or stabilization in clinical signs and symptoms of disease.

# Medical Policy

## Healthcare Services Department

Policy Name	Policy Number	Scope
Mirikizumab-mrkz (Omvoh®)	MP-RX-FP-125-24	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

### C. Authorization Duration

- i. Initial Approval Duration: Up to 12 months
- ii. Reauthorization Approval Duration: Up to 12 months

### D. Conditions Not Covered

*Any other use is considered experimental, investigational, or unproven, and may not be approved including the following (this list may not be all inclusive):*

- i. In combination with topical or oral JAK inhibitors, apremilast, deucravacitinib, ozanimod, etrasimod, or any of the following biologic immunomodulators: TNF antagonists, other IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, abatacept, IL-1 inhibitors, IL-6 inhibitors, rituximab or natalizumab; **OR**
- ii. Tuberculosis, other active serious infections, or a history of recurrent infections [repeat TB testing not required for ongoing therapy]; **OR**
- iii. If initiating therapy, Individual has not had a tuberculin skin test (TST) or a Centers for Disease Control (CDC-) and Prevention - recommended equivalent to evaluate for latent tuberculosis (unless switching therapy from another targeted immune modulator and no new risk factors); **OR**
- iv. When the above criteria are not met and for all other indications.

### Limits or Restrictions

#### A. Therapeutic Alternatives

*The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.*

- i. N/A

#### B. Quantity Limitations

*Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.*

# Medical Policy

## Healthcare Services Department

Policy Name	Policy Number	Scope
Mirikizumab-mrkz (Omvoh®)	MP-RX-FP-125-24	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Mirikizumab-mrkz (Omvoh®)

Drug	Limit	Recommended Dosing Schedule
Omvoh (mirikizumab-mrkz) 100 mg/mL prefilled SD pen/syringe	2 pens/syringes per 28 days (4 weeks)	<ul style="list-style-type: none"><li>• Induction dosage: 300 mg administered by intravenous infusion at weeks 0, 4 and 8.</li><li>• Maintenance dosage: 200 mg administered by subcutaneous injection (2 injections of 100 mg each) at Week 12, and every 4 weeks thereafter.</li></ul>
Omvoh (mirikizumab-mrkz) 300 mg/15 mL (20mg/mL) SDV	3 vials total to last 12 weeks	
Exceptions		
<ul style="list-style-type: none"><li>• Patients should be evaluated for tuberculosis (TB) infection prior to initiating treatment with Omvoh.</li><li>• Liver enzymes and bilirubin levels should be monitored at baseline and for at least 24 weeks of treatment.</li><li>• Complete all age-appropriate vaccinations according to current immunization guidelines (avoid live vaccines).</li></ul>		

## Reference Information

- Centers for Disease Control and Prevention (CDC). Tuberculosis (TB). Available at: <https://www.cdc.gov/tb/topic/basics/risk.htm>. Last updated: March 18, 2016. Accessed October 15, 2023.
- DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 27, 2023.
- DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- Feuerstein JD, Ho EY, Shmidt E et al. American Gastroenterological Association Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. *Gastroenterology* 2021; 160:2496-2508.
- Feuerstein JD, Issacs KL, Schneider Y, et al. American Gastroenterological Association Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. *Gastroenterology* 2020; 158:1450-1461.
- Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
- Lichtenstein GR, Loftus EV, Isaacs KL et al. 2018 American College of Gastroenterology Guideline for the management of Crohn's disease in adults. *Am J Gastroenterol* 2018; 113:481-517.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019; 80: 1029-72.
- Rubin DT, Ananthakrishnan AN, Siegel CA et al. American College of Gastroenterology Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol* 2019; 114:384-413.
- Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheum*. 2019; 71(1): 5-32.

# Medical Policy

## Healthcare Services Department

<b>Policy Name</b> <b>Mirikizumab-mrkz (Omvoh®)</b>	<b>Policy Number</b> MP-RX-FP-125-24	<b>Scope</b> <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
--	---	--

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

### Policy History

Revision Type	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review 12/23/2024	Update and clarify quantity limits table based on approved dosage forms. Wording and formatting changes. Added vaccination recommendation per FDA label. Coding Reviewed: Removed HCPCS J3590. Added J2267 for Omvoh. Added ICD10-DM K51.00-K51.919.	3/20/2025	4/2/2025
Policy Inception 01/29/2024	Elevance Health's Medical Policy adoption	N/A	6/28/2024